Miransertib Mesylate is a small molecule commercialized by Merck, with a leading Phase I program in Ovarian Cancer;Endometrial Cancer. According to Globaldata, it is involved in 7 clinical trials, of which 4 were completed, 1 is ongoing, and 2 were terminated. GlobalData uses proprietary data and analytics to provide a complete picture of Miransertib Mesylate’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for Miransertib Mesylate is expected to reach an annual total of $17 mn by 2038 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Miransertib Mesylate Overview
Miransertib mesylate (ARQ-092) is under development for the treatment of proteus syndrome, PIK3CA-related overgrowth spectrum (PROS), sickle cell disease, solid tumors including ovarian cancer, endometrial cancer, lymphoma, hepatocellular carcinoma, melanoma and other rare diseases. The drug candidate is a new molecular entity administered orally. It acts on protein kinase B (PKB or Akt). It is developed by using AKIP technology platform. The technology is a Kinase inhibitor platform that is based on a novel binding mode that leads to inhibition of target kinases by small molecules that do not compete with adenosine triphosphate (ATP) for binding. It was also under development for the treatment of gastrointestinal stromal tumor, cervical cancer, breast cancer, colorectal cancer and neuroendocrine cancer.
Merck Overview
Merck is a biopharmaceutical company with focus on the discovery, development, manufacturing and marketing of prescription medicines, biologic therapies, vaccines, and animal health products. It offers prescription products for the treatment of cardiovascular conditions, cancer, immune disorders, infectious and respiratory diseases, and diabetes, among others. The company provides animal health products such as vaccines, poultry products, livestock products and aquaculture products. Merck sells medicines to drug wholesalers, retailers, hospitals, government agencies and managed health care providers; and animal health products to veterinarians, distributors, and animal producers. The company and its subsidiaries operate in the Americas, Europe, the Middle East, Africa, Asia Pacific, and Latin America. Merck is headquartered in Rahway, New Jersey, the US.
The company reported revenues of (US Dollars) US$60,115 million for the fiscal year ended December 2023 (FY2023), an increase of 1.4% over FY2022. In FY2023, the company’s operating margin was 3%, compared to an operating margin of 30.3% in FY2022. In FY2023, the company recorded a net margin of 0.6%, compared to a net margin of 24.5% in FY2022.
The company reported revenues of US$16,112 million for the second quarter ended June 2024, an increase of 2.1% over the previous quarter.
For a complete picture of Miransertib Mesylate’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.